ArticleGut1998
Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
Article in Gut, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic and prognostic value of Bcl-2 in uterine leiomyosarcoma.Archives of gynecology and obstetrics · 2023Pooled it
- High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis.World journal of gastroenterology · 2017Pooled it
- Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer.Cancers · 2020Review
- POFUT1 promotes colorectal cancer development through the activation of Notch1 signaling.Cell death & disease · 2018Article
- The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.Cell death discovery · 2015Article
- The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.Biomarkers in cancer · 2013Review
- Comparative proteomic study for profiling differentially expressed proteins between Chinese left- and right-sided colon cancers.Cancer science · 2013Article
- Expression Profiling of Proliferation and Apoptotic Markers along the Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis Patients.Gastroenterology research and practice · 2013Article
- [Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy].Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2005Review
- Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2005Article
- Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.International journal of colorectal disease · 2004Review
- Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.Digestive diseases and sciences · 2003Article
- Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.Leukemia · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the association between immunohistochemical expression of Bcl-2 and p53 in colorectal cancer and tumour recurrence following surgery.
methodsSixty six cases of Dukes' B colorectal carcinoma were studied. All tumours were moderately differentiated and were shown to be histologically clear of the resection margins. Immunohistochemistry was performed on formalin fixed paraffin wax embedded tissue using monoclonal antibodies for p53 and Bcl-2. The Bcl-2 staining was assessed separately for relative intensity of staining and percentage of positive tumour cells and given a final score which combined the two factors. The p53 staining was assessed on number of positive tumour cells only. The patterns of immunostaining of those cases in which there had been tumour recurrence were compared with those cases in which there was no tumour recurrence (controls).
resultsA statistically significant inverse association was found between Bcl-2 score and tumour recurrence (median Bcl-2 score of 6 (interquartile range (IQR) 2-9) in patients with recurrent disease; median Bcl-2 score of 8 (IQR 6-10) in those without recurrence; p = 0.03). When examined separately, both the intensity of expression and percentage of positive tumour cells were significantly associated with tumour recurrence (p = 0.04 in each case). There was no association between p53 staining and tumour recurrence.
conclusionResults suggest that, when controlled for differentiation, Bcl-2 expression is a prognostic marker and may be useful as an adjunctive test in clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.